© 2022 MJH Life Sciences and CGTLive™. All rights reserved.
© 2022 MJH Life Sciences™ and CGTLive™. All rights reserved.
Review top news and interview highlights from the week ending May 20, 2022.
Catch up on the latest news and announcements in cell and gene therapies presented at the annual ASGCT meeting.
Interim data from the phase 2 Skyline trial demonstrated a 62.5% response rate.